Long-term effects of duodenojejunal bypass on diabetes in Otsuka Long-Evans Tokushima Fatty rats

Asian Journal of Surgery
Sang Kuon LeeSay-June Kim

Abstract

Previous studies have shown that duodenojejunal bypass (DJB) resolves type 2 diabetes. However, this finding has been contradicted by several experimental and human trials and therefore needs to be clarified. Otsuka Long-Evans Tokushima Fatty (OLETF) rats randomly underwent a sham operation or DJB. Thereafter, we measured daily body weight, serum levels of glucose and gut hormones such as glucagon-like peptide-1, insulin, and leptin. There was no significant difference in weight loss between rats in the DJB and sham-operated groups. There were also no differences in the area under the curve of glucose tolerance between the DJB and sham-operated groups (32466 ± 2261 mg/dL·min vs. 26319 ± 427 mg/dL·min; p = 0.35). Duodenojejunal bypass did not affect plasma concentrations of various gut hormones such as glucagon-like peptide-1, insulin, and leptin. We have shown that DJB alone does not improve glucose tolerance in obese, diabetic OLETF rats. Therefore, it may be that DJB alone is insufficient for diabetic control in obese diabetic rats. The addition of a restrictive component such as sleeve gastrectomy, or a new drug may be necessary for achieving diabetes reversal.

References

May 1, 1976·The Tohoku Journal of Experimental Medicine·Y GotoN Masaki
May 25, 1995·Biochemical and Biophysical Research Communications·A FunakoshiA Kono
Oct 1, 1994·Diabetes Research and Clinical Practice·K KawanoT Natori
Sep 22, 2000·Annals of Surgery·P R SchauerJ Luketich
Nov 1, 2000·Nature·M TschöpM L Heiman
Feb 24, 2001·Nature·M NakazatoS Matsukura
May 10, 2001·World Journal of Surgery·W J Pories, R J Albrecht
Oct 16, 2001·The Journal of Clinical Endocrinology and Metabolism·F BroglioE Ghigo
Nov 29, 2001·The Journal of Biological Chemistry·Masahiro MurataKazuo Chihara
Dec 11, 2002·JAMA : the Journal of the American Medical Association·Robert E Brolin
Jun 11, 2003·Annals of Surgery·Harvey J SugermanJohn N Clore
Oct 8, 2003·Annals of Surgery·Philip R SchauerDavid Kelley
Sep 30, 2004·American Journal of Physiology. Endocrinology and Metabolism·April D StraderRandy J Seeley
Nov 6, 2004·Obesity Surgery·Henry Buchwald, Stanley E Williams
Jan 15, 2008·Physiology & Behavior·Timothy H Moran
Jun 3, 2009·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Tammy L KindelPatrick Tso
Nov 10, 2009·Diabetes Research and Clinical Practice·J E ShawP Z Zimmet
Jun 1, 2010·Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery·Mary DiGiorgiMarc Bessler
Jul 17, 2010·American Journal of Physiology. Gastrointestinal and Liver Physiology·Derek M CulnanRobert N Cooney
Jan 28, 2015·Scandinavian Journal of Surgery : SJS : Official Organ for the Finnish Surgical Society and the Scandinavian Surgical Society·A MaleckasL Fändriks

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.